Heather Bresch, Mylan NV - CEO
Okay. Hi, Sumant. So as far as EpiPen is concerned, we are factoring in or assuming a BX approval in the second half of the year. Again, I think we've been pretty vocal on the high bar, that we believe an AB rated brings. But any way, those are the assumptions that are built into our 2016. And then, as far as Auvi-Q, again I think it was an extremely unprecedented action that took place. And all I can say, it's I think unprecedented to try to come back from something like that. But again, I don't want to
speak for Sanofi, but we certainly, haven't heard anything about them contemplating any kind of reentry.
orex is down again . $ .13 . Nothing uplifting. $200M for the trial and NO PARTNER!
Sharon... : thanks and also do you know when the bill, that is before the Congress regarding Obesity, will be voted upon ?
devi... : Apparently you can not read English! OR, maybe, your comprehension is very poor!
Something big is going on that we are not or partially aware. " I believe that we are poised to deliver on several catalysts over the next 12 months including the mid-year launch of the sumatriptan auto injector, the filing of the QuickShot testosterone new drug application with the U.S. FDA, a potential approval and launch of the epinephrine auto injector and
growth in our alliance business through additional collaborations," Apple said in the company's press release.
tappy... : Do you think that , the FDA , talks in riddles ? What are you talking about ? Are you working for the ATRS management? Do you think TEVA is a newborn baby who would not , immediately , know what the FDA is saying or implying in the CRL?